Results 71 to 80 of about 208,148 (266)
Chronic myeloid leukemia-clinical, experimental and health economic studies with special reference to imatinib treatment [PDF]
, 2013 CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting hematopoiesis, particularly resulting in ...
Ohm, Lotta
core +1 more source
Chlorogenic Acid: An In‐Depth Review of Its Effectiveness in Cancer Treatment
Cancer Nexus, Volume 1, Issue 1, April 2025.ABSTRACT Cancer remains a formidable global health challenge. Owing to the unsatisfactory curative effects and severe side effects, it is urgent to explore safer and more effective therapeutic alternatives and drugs. Chlorogenic acid (CGA), a natural polyphenol, has emerged as a promising candidate for cancer therapy due to its multiple functions and ...
Bin Wang +9 more
wiley +1 more source
Chronic myeloid leukemia: past, present, future [PDF]
Einstein (São Paulo), 2011 The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann +1 more
doaj +4 more sources
Acta Médica Portuguesa, 2019 Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida +10 more
doaj +1 more source
Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]
PLoS ONE, 2012 BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle +6 more
doaj +1 more source
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein [PDF]
, 2013 Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen ...
Alessandro Pandini +11 more
core +1 more source
Advances in reversible covalent kinase inhibitors
Medicinal Research Reviews, Volume 45, Issue 2, Page 629-653, March 2025.Abstract Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects.
Zheng Zhao, Philip E. Bourne
wiley +1 more source
Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia [PDF]
Farmacia Hospitalaria, 2015 Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia.
Begoña San José Ruiz +2 more
doaj +1 more source
Clinical and Translational Science, Volume 18, Issue 3, March 2025.ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis
Andrew G. Hadd +18 more
wiley +1 more source
Biomolecular Concepts, 2021 The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome +3 more
doaj +1 more source